Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum’s core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control.
Adverum Biotechnologies NASDAQ:
07/24/21 3:38 PM EDT
Data provided by Nasdaq.
Minimum 15 minutes delayed.
- Jul 22 2021
Summary ToggleAdverum Provides Update on ADVM-022 and the INFINITY Trial in Patients with Diabetic Macular Edema
- Jul 1 2021
Summary ToggleAdverum Announces Appointment of Jon Williams, Ph.D., as Vice President, Clinical Affairs
- Jun 24 2021
Summary ToggleAdverum Announces Changes to Management Team
- Jun 1 2021
Summary ToggleAdverum Appoints CMO and CSO
There are currently no events to display.